Sign in Subscribe
Pharmaceutical industry

Pfizer and Debiopharm Partner to Develop Cancer Treatment for Melanoma

Strategic Insights

— 1 min read

Pfizer and Debiopharm have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. The partnership aims to leverage the combined expertise of both companies in developing a personalized medicine for cancer patients. "The continuation of the clinical development of tremelimumab with our partner, Debiopharm, is a demonstration of our commitment to personalized medicine for cancer patients," said Garry Nicholson, president and general manager of Pfizer's Oncology Business Unit.

Key Takeaways:

  • Pfizer and Debiopharm will conduct a Phase 3 trial of tremelimumab (CP675,206) for the treatment of patients with unresectable, Stage IV melanoma.
  • Debiopharm will assume responsibility for conducting the phase 3 trial, while Pfizer will retain responsibility for worldwide commercialization of the compound.
  • The partnership aims to leverage the combined expertise of both companies in developing a personalized medicine for cancer patients.
  • Tremelimumab (CP675,206) is a fully human igG2 monoclonal antibody that has been in development for the treatment of advanced melanoma.
  • The number of melanoma cases worldwide is increasing faster than any other cancer, with about 69,000 patients diagnosed in the United States each year.
  • Analysis of data from a previous Phase 3 clinical trial identified a biomarker that will be used in patient selection for the upcoming trial.
  • The partnership demonstrates a commitment to personalized medicine for cancer patients, according to Garry Nicholson, president and general manager of Pfizer's Oncology Business Unit.

Statistics:

  • 69,000 patients are diagnosed with melanoma in the United States each year ([1]).
  • The number of melanoma cases worldwide is increasing faster than any other cancer ([1]).
  • Tremelimumab (CP675,206) is currently in Phase 2 clinical development ([2]).
  • Pfizer has more than 25 biologics and small molecules in clinical development ([3]).
  • Over 200 clinical trials are underway at Pfizer Oncology ([3]).

Sources:

[1] Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206).

[2] Pfizer Inc.: Working together for a healthier world.

[3] Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.

Read more